Design and synthesis of novel hydrazide-linked bifunctional peptides as δ/μ opioid receptor agonists and CCK-1/CCK-2 receptor antagonists

Journal of Medicinal Chemistry

Volumn 49, Issue 5, 2006, Pages 1773-1780

  Lee, Yeon Sun ^a   Agnes, Richard S ^a   Badghisi, Hamid ^b   Davis, Peg ^b   Ma, Shou Wu ^b   Lai, Josephine ^b   Porreca, Frank ^b   Hruby, Victor J ^a  

^a University of Arizona   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; DELTA OPIATE RECEPTOR; G PROTEIN COUPLED RECEPTOR; HYDRAZIDE DERIVATIVE; MU OPIATE RECEPTOR; OPIATE AGONIST;

AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING, COMPETITIVE; CELL LINE; CRICETINAE; CRICETULUS; DRUG DESIGN; GUINEA PIGS; HUMANS; HYDRAZINES; ILEUM; LIGANDS; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; OLIGOPEPTIDES; RADIOLIGAND ASSAY; RATS; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33644863475     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050851n     Document Type: Article

References (36)

1. Wiesenfeld-Hallin, Z.; Lucas, G. A.; Alster, P.; Xu, X.-J.; Hokfelt, T. Cholecystokinin/opioid interaction. Brain Res. 1999, 848, 78-89.
2. Itoh, S.; Katsuura, G.; Maeda, Y. Caerulein and cholecystokinin suppress β-endomorphin-induced analgesia in the rat. Eur. J. Pharmacol. 1982, 80, 421-425.
3. Dickenson, A. H. Mechanisms of the analgesic actions of opiates and opioids. Br. Med. Bull. 1991, 47, 690-702.
4. Paris, P. L.; Komisaruk, B. P.; Watkins, L. R.; Mayer, D. J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 1983, 219, 310-312.
5. Heinricher, M. M.; Neubert, M. J. Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J. Neurophysiol. 2004, 92, 1982-1989.
6. Lu, L.; Huang, M.; Liu, A.; Ma, L. Cholecystokinin-B receptor antagonists attenuate morphine dependence and withdrawal in rats. Neuroreport 2000, 11, 829-832.
7. Suberg, S. N.; Culhane, E. S.; Carstens, E.; Watkins, L. R. The potentiation of morphine-induced inhibition of spinal transmission by proglumide, a putative cholecystokinin antagonist. Ann. N. Y. Acad. Sci. 1985, 448, 660-662.
8. Watkins, L. R.; Kinscheck, I. B.; Mayer, D. J. Potentiation of opiate analgesia and apparent reversal of morphine tolerance by proglumide. Science 1984, 224, 395-396.
9. 2 with μ and δ opioid antinociception in the rat spinal cord. Neuropeptides 1990, 16, 213-218.
10. Lee, Y. S.; Agnes, R. S.; Davis, P.; Ma, S.-W.; Lai, J.; Porreca, F.; Hruby, V. J. Hydrazide linked bifunctional peptides for the treatment of pain. In Peptide Revolution: Genomics, Proteomics & Therapeutics; Chorev, M., Sawyer, T. K., Eds.; Kluwer Academic Publishers: Dordrecht, 2004; pp 615-616.
11. Hruby, V. J.; Agnes, R. S.; Davis, P.; Ma, S.-W.; Lee, Y. S.; Vanderah, T. W.; Lai, J.; Porreca, F. Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain. Life Sci. 2003, 73, 699-704.
12. 26-33 selective for B-type CCK receptors possess opioid receptor agonist activity in vitro and in vivo: Evidence for similarities in CCK-B and opioid receptor requirements. In Peptides, Chemistry, Structure and Biology; Hodges, R. S., Smith, J. A, Eds.; Escom: Leiden, 1993; pp 669-671.
13. Nikiforovich, G. V.; Hruby, V. J. Examination of the conformational meaning of "δ-address" in the dermenkephalin sequence. Biochem. Biophys. Res. Commun. 1990, 173, 521-527.
14. Slaninova, J.; Knapp, R. J.; Wu, J.; Fang, S. N.; Kramer, T.; Hruby, V. J.; Yamamura, H. I. Opioid receptor binding properties of analgesic analogues of cholecystokinin octapeptide. Eur. J. Pharmacol. 1991, 200, 195-198.
15. Horan, P. J.; Mattia, A.; Bilsky, E. J.; Weber, S.; Davis, T. P.; Yamamura, H. J.; Malatynska, E.; Appleyard, S. M.; Slaninova, J.; Misicka, A.; Lipkowski, A. W.; Hruby, V. J.; Porreca, F. Antinociceptive Profile of biphalin, a dimeric enkephalin Analog. J. Pharmacol. Exp. Ther. 1993, 265, 1446-1454.
16. Martinez, J.; Rodriguez, M.; Lignon, M. F.; Galas, M. C.; Amblard, M.; Rolland, M.; Mendre, C.; Fulcrand, P.; Laur, J.; Bernad, N. Structure activity relationship of cholecystokinin: Analogs exhibiting selective activity. J. Pharm. Belg. 1991, 46, 9-16.
17. Singh, L.; Oles, R. J.; Field, M. J.; Atwal, P.; Woodruff, G. N.; Hunter, J. C. Effect of CCK receptor antagonists on the antinociceptive reinforcing and gut motility properties of morphine. Br. J. Pharmacol. 1996, 118, 1317-1325.
18. Ghilardi, J. R.; Allen, C. J.; Vigna, S. R.; Mcvey, D. C.; Mantyh, P. Trigeminal dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit, and monkey: Possible site of opiate-CCK analgesic interactions. J. Neurosci. 1992, 12, 4854-4866.
19. 125I-cholecystokinin in primate spinal cord are of the CCK-A subclass. Neurosci. Lett. 1998, 89, 133-139.
20. Quock, R. M.; Burkey, T. H.; Varga, E.; Hosohata, Y.; Hosohata, K.; Cowell, S. M.; Slate C. A.; Ehlert, F. J.; Roeske, W. R.; Yamamura, H. I. The δ opioid receptor: Molecular pharmacology, signal transduction and the determination of drug efficacy. Pharmacol. Rev. 1999, 51, 503-532.
21. Dal Forno, G.; Pietra, C.; Urciuoli, M.; van Amsterdam, f. T.; Toson, G. Evidence for two cholecystokinin receptors mediating the contraction of the guinea pig isolated ileum longitudinal muscle nuenteric plexus. J. Pharmacol Exp. Ther. 1992, 261, 1056-1063.
22. Dunlop, J. CCK receptor antagonists. Gen. Pharm. 1998, 31, 519-524.
23. 2 (A-71623). J. Med. Chem. 1995, 38, 207-211.
24. Pan, G.-Z.; Martinez, J.; Bodansky, M.; Jensen, R. T.; Gardner, J. D. The importance of the amino acid in position 32 of cholecystokinin in determining its interaction with cholecystokinin receptors on pancreatic acini. Biochim. Biophys. Acta 1981, 678, 352-357.
25. Low, C. M. R.; Black, J. W.; Broughton, H. B.; Buck, I. M.; Davies, J. M. R.; Dunstone, D. J.; Hull, R. A. D.; Kalindjian, S. B.; McDonald, I. M.; Pether, M. J.; Shankley, N. P.; Steel, K. I. M. Development of peptide 3D structure mimetics: Rational design of novel peptoid cholecystokinin receptor antagonist. J. Med. Chem. 2000, 43, 3505-3517.
26. Elliott, R. L.; Kopecka, H.; Bennett, M. J.; Shue, Y.-K.; Craig, R.; Lin, C.-W.; Bianchi, B. R.; Miller, T. R.; Witte, D. G.; Stashko, M. A.; Asin, K. E.; Nikkel, A.; Bednarz, L.; Nadzan, A. M. Tetrapeptide CCK agonist: Structure-activity studies on modifications at the N-terminus. J. Med. Chem. 1994, 37, 309-313.
27. Hruby, V. J.; Fang, S.; Knapp, R.; Kazmierski, W.; Lui, G. K. Cholecystokinin analogues with high affinity and selectivity for brain membrane receptors. Int. J. Pept. Protein Res. 1990, 35, 566-573.
28. Alves, I.; Cowell, S.; Lee, Y. S.; Tang, C.; Davis, P.; Porreca, P.; Hruby, V. J. A Novel 3-step enantioselective synthesis of pyrenylalanine with subsequent incorporation into opioid, CCK, and melanotropin ligands. Biochem. Biophys. Res. Commun. 2004, 318, 335-340.
29. Shimohigashi, Y.; Costa, T.; Chen, H. C.; Rodbard, D. Dimeric tetrapeptide enkephalins display extraordinary selectivity for the δ opiate receptor. Nature 1982, 297, 333-335.
30. Horwell, D. C.; Beeby, A.; Clark, C. R.; Hughes, J.; Synthesis and binding affinities of cholecystokinin (30-33) as probes for central nervous system cholecystokinin receptors. J. Med. Chem. 1987, 30, 729-732.
31. Lai, J.; Ma, S.-W.; Zhu, R.-H.; Rothman, R. B.; Lentes, K. U.; Porreca, F. Pharmacological characterization of the cloned kappa opioid receptor as a kappa 1b subtype. NeuroReport. 1994, 5, 2161-2164.
32. 35S]thio)triphosphate binding. Mol. Pharmacol. 1993, 44, 115-123.
33. Polt, R.; Porreca, F.; Szabo, L.; Bilsky, E. J.; Davis, P.; Davis, T.; Horvath, R.; Abbruscato, T. J.; Yamamura, H. J.; Hruby, V. J. Glycopeptide enkephalin analogues produce analgesia in mice: Evidence for penetration of the blood-brain barrier. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 7114-7118.
34. Misicka, A.; Lipkowski, A. W.; Horvath, R.; Davis, P.; Kramer, T. H.; Yamamura, H. I.; Hruby, V. J. Topographical requirements for delta opioid ligands: Common structural features of dermenkephalin and deltorphin. Life Sci. 1992, 51, 1025-1032.
35. Kramer, T. H.; Shook, J. E.; Kazmierski, W. K.; Ayres, E. A.; Wire. W. S.; Hruby, V. J.; Burks, T. F. Novel peptidic mu opioid antagonists: Pharmacologic characterization in vitro and in vivo. J. Pharmacol. Exp. Ther. 1989, 249, 544-551.
36. Porreca, F.; Burks, T. F. The spinal cord as a site of opioid effects on gastrointestinal transit in the mouse. J. Pharmacol. Exsp. Ther. 1983, 227, 22-27.